Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Commentary : Patient’s Voice
Corrigendum
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letter to the Editor – Authors’ reply
Letters to Editor
Literature Review
Nephrology in India
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Commentary : Patient’s Voice
Corrigendum
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letter to the Editor – Authors’ reply
Letters to Editor
Literature Review
Nephrology in India
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
View/Download PDF

Translate this page into:

Letters to Editor
25 (
6
); 391-392
doi:
10.4103/0971-4065.160338

Association of clinical presentation with anti-nuclear antibody specificities among patients with systemic lupus erythematosus

Clinical and Experimental Immunology, National Institute of Immunohaematology, Indian Council of Medical Research, King Edward Memorial Hospital, Parel, Mumbai, Maharashtra, India
Department of Medicine, King Edward Memorial Hospital, Parel, Mumbai, Maharashtra, India
INSERM, UMR-S 1138, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie, Paris 6, F-75006, France

Address for correspondence: Dr. V. Pradhan, Clinical and Experimental Immunology, National Institute of Immunohaematology, Indian Council of Medical Research, King Edward Memorial Hospital, Parel, Mumbai, Maharashtra, India. E-mail: pradhanv69@rediffmail.com

Licence

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.

Sir,

Systemic lupus erythematosus (SLE) is characterized by the production of a wide range of autoantibodies directed against a multiplicity of autoantigens. Anti-nuclear antibody (ANA) test by immune fluorescence assay (IFA) is the gold standard test while ANABLOT detects the majority of autoantibodies in SLE patients. The human epithelial carcinoma-2 cell line is used to detect ANAs, which gives different patterns according to the antigens against which autoantibodies are produced. These autoantibodies are detected by indirect IFA.[1] Strong associations between ANA specificities and IFA patterns have been observed. Specificity for anti-dsDNA, histone, and DNA/histone gives homogeneous-ANA (H-ANA) pattern, whereas Sn-RNP, SmD1, U1RNA give speckled-ANA (S-ANA) pattern. Other patterns observed are nucleolar-ANA (N-ANA) and cytoplasmic-ANA (C-ANA) pattern.[23]

This study included 100 (96 females) patients with SLE (mean age of onset 27 ± 9.5 years) where in the association between ANA specificities and clinical presentations were studied. The mean SLEDAI score at clinical evaluation was 6.0 ± 7.5. These patients Were further categorized as lupus nephritis (LN) (n = 56) and SLE without nephritis (n = 44) based on WHO criteria. ANA was tested by IFA using commercial kits from AESKUSLIDES, Germany and ANA specificities were detected by ANABLOT, AESKUBLOTS, Germany. The association between autoantibody specificities and clinical manifestations were calculated by Fisher's exact test. Frequency of ANA, anti-dsDNA autoantibodies were 100% and 84%, respectively. Out of 100 SLE patients studied, H-ANA pattern was seen in 75% patients, S-ANA in 19% N-ANA in 4%, and C-ANA pattern in 2% patients by IFA. H-ANA pattern and dsDNA autoantibody positivity was strongly associated with clinical manifestations such as renal manifestations (odds ratio [OR] =10, P = 0.0026), malar rash (OR = 4.444, P = 0.046), with oral ulcers (OR = 25.6, P = 0.0014). Similarly, H-ANA pattern and anti-SmD1 antibody positivity was also associated with malar rash (OR = 9.318, P = 0.003), oral ulcer (OR = 7.625, P = 0.0376). Also H-ANA pattern and anti-Ro/SS-A antibodies were associated with photosensitivity (OR = 8.167, P = 0.0113) [Table 1].

Table 1 Association of ANA specificities (by ANA BLOT) with clinical manifestations in SLE patients (n=100) and with H-ANA pattern (n=75)

There are ethnic differences in association of clinical manifestations and ANA specificities. In a study from Sweden, S-ANA pattern was reported to be less associated with anti-dsDNA antibodies as compared to organ damage and H-ANA pattern among LN patients. The present study showed an association of H-ANA pattern with malar rash, photosensitivity and oral ulcers with multiple ANA specificities. Till today, the entire geoepidemiological picture of SLE showing variations in the clinical manifestations and associated autoantibodies is not clear in India. More reports from different regions of the country are needed to throw light on the association of clinical manifestations and ANA specificities.[45]

Acknowledgment

We are grateful to ICMR-INSERM for providing financial support to conduct this work under the International Associated Laboratories (IAL) program.

References

  1. , , . Systemic lupus erythematosus. N Engl J Med. 2008;358:929-39.
    [Google Scholar]
  2. , . Clinical relevance of autoantibodies in systemic rheumatic diseases. MolBiol Rep. 1996;23:133-45.
    [Google Scholar]
  3. , , , , . Anti-Sm: Its predictive value in systemic lupus erythematosus. ClinRheumatol. 1993;12:350-3.
    [Google Scholar]
  4. , , , , , . Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: Analysis of a regional Swedish register. BMJ Open. 2013;3:e003608.
    [Google Scholar]
  5. , , , , , , . Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: Significant factors associated with lupus nephritis. Ann Rheum Dis. 2003;62:556-60.
    [Google Scholar]

    Fulltext Views
    267

    PDF downloads
    527
    View/Download PDF
    Download Citations
    BibTeX
    RIS
    Show Sections